BioCardia Completes FDA Pre-Submission for Helix Transendocardial Delivery Catheter

2026-02-10 10:31:15 ET

BioCardia, Inc. (Nasdaq: BCDA) , a developer of cellular and cell-derived therapies for cardiovascular and pulmonary diseases, has taken an important regulatory step forward. Specifically, the company announced it has completed a Pre-Submission to the U.S. Food and Drug Administration (FDA) under the agency's Q-Submission program for its Helix(TM) Transendocardial Delivery Catheter.

This milestone represents meaningful progress toward FDA clearance of the Helix catheter, which is designed for the targeted intramyocardial delivery of therapeutic and diagnostic agents. Importantly, the Pre-Submission is supported by data from fifteen well-controlled clinical trials that utilized the Helix system for cell and gene therapy delivery to the heart. Collectively, these studies enrolled patients across three major cardiac indications, thereby providing substantial evidence of the device's safety profile and clinical performance.

Moreover, the Helix Pre-Submission is directly tied to the CardiAMP(R) Cell Therapy System, which has already received FDA Breakthrough Device Designation. As a result, BioCardia expects to engage with the FDA over the next 45 days to align on the regulatory pathway and approval timeline. If discussions proceed as anticipated, the company may be positioned to submit a market clearance application in the near term.

Commenting on the development, BioCardia President and CEO Dr. Peter Altman highlighted the broader implications of the filing. He noted that FDA clearance of Helix could make it the first approved transendocardial delivery catheter system in the United States. Furthermore, such approval would streamline future regulatory submissions for BioCardia's autologous and allogeneic cell therapies targeting heart failure and chronic myocardial ischemia. In addition, it could reduce development risk for biotechnology and pharmaceutical partners seeking advanced delivery solutions for cardiovascular cell, gene, and protein therapies.

A Differentiated Delivery Platform

At the center of BioCardia's innovation is the Helix Transendocardial Delivery Catheter, a minimally invasive platform engineered for precise, targeted delivery directly into heart tissue. Unlike alternative delivery approaches, Helix enables superior agent retention while also reaching myocardial regions that are otherwise inaccessible.

This precision is made possible by the catheter's proprietary small distal helical needle. By engaging the heart tissue from within the cardiac chamber, the needle provides stability despite the constant motion of a beating heart. Consequently, physicians are able to deliver therapeutic agents safely and effectively in a highly controlled manner.

The Helix system is designed for use by trained interventional cardiologists, electrophysiologists, and cardiac surgeons experienced in endovascular and transendocardial procedures. Notably, independent clinical reviews have shown that Helix offers superior procedural safety compared to other transendocardial delivery catheters. Additionally, preclinical studies have demonstrated a three-fold increase in effective dosing versus open surgical intramyocardial delivery and an eighteen-fold increase compared with intracoronary artery infusion.

To further enhance maneuverability and precision, the Helix catheter is paired with BioCardia's FDA-approved Morph(R) DNA(TM) steerable introducer, which provides physicians with advanced navigation control within the heart.

Positioning BioCardia for Long-Term Growth

Based in Sunnyvale, California, BioCardia continues to focus on advancing therapies for cardiovascular and pulmonary diseases with significant unmet medical needs. Its lead biotherapeutic platforms--CardiAMP(R) autologous and CardiALLO(TM) allogeneic cell therapies--include three cardiac clinical-stage programs currently under development. These therapies are enabled by the company's proprietary Helix(TM) delivery and Morph(R) vascular navigation technologies.

Taken together, the completion of the Helix FDA Pre-Submission represents not only a regulatory milestone, but also a strategic step that could accelerate BioCardia's broader therapeutic pipeline. As discussions with the FDA progress, the company appears increasingly well-positioned to advance both its device platform and its regenerative medicine programs toward commercialization.

About the Helix Transendocardial Delivery Catheter

The Helix Transendocardial Delivery Catheter is a groundbreaking platform designed for the minimally invasive, targeted delivery of therapeutic and diagnostic agents directly to the heart. What sets Helix apart is its ability to deliver agents precisely within the heart tissue, ensuring superior retention compared to other delivery methods. Furthermore, it can access regions of the heart that are otherwise unreachable by alternative delivery techniques.

At the core of the Helix catheter's innovation is its specialized small distal helical needle. This needle engages heart tissue from within the heart chamber, providing stability even within the dynamic environment of a beating heart. This stability enables safe and effective delivery of therapeutic agents.

The Helix catheter is intended for use by interventional cardiologists, electrophysiologists, and cardiac surgeons trained in endovascular and transendocardial procedures. Independent reviews of clinical experience with Helix have highlighted its superior procedural safety compared to other transendocardial delivery catheters. Additionally, pre-clinical studies have demonstrated that the Helix catheter achieves a three-fold increase in effective dosing compared to open surgical access intramyocardial delivery and an eighteen-fold increase compared to intracoronary artery infusion.

To further enhance its capabilities, the Helix catheter is complemented by BioCardia's FDA-approved Morph(R) DNA(TM) steerable introducer. This device provides physicians with superior control when navigating the Helix catheter within the heart.

About BioCardia

Headquartered in Sunnyvale, California, BioCardia, Inc. is at the forefront of developing cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. The company's biotherapeutic platforms, CardiAMP(R) autologous and CardiALLO(TM) allogeneic cell therapies, include three cardiac clinical-stage product candidates currently in development. These therapies are enabled by BioCardia's Helix(TM) biotherapeutic delivery and Morph(R) vascular navigation platforms.

With its innovative technologies and commitment to addressing unmet medical needs, BioCardia continues to advance the field of cardiovascular and pulmonary therapeutics. For more information, visit www.BioCardia.com .

 

The post BioCardia Completes FDA Pre-Submission for Helix Transendocardial Delivery Catheter appeared first on PRISM MarketView .

COMTEX_473269040/2927/2026-02-10T10:31:15